Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-IL-4 neutralizing monoclonal antibody
- Development stage
- Discontinued
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intraperitoneal, Intratumoral, Intravenous, Subcutaneous
01
Overview
An anti-IL-4 neutralizing monoclonal antibody is a type of biologic therapy designed to bind to and neutralize interleukin-4 (IL-4), a key cytokine involved in type 2 (Th2) immune responses. By blocking IL-4, these antibodies inhibit downstream signaling pathways, such as JAK-STAT6, thereby reducing Th2 cell differentiation, immunoglobulin E (IgE) production, and alternative (M2) macrophage activation. This class of therapeutic agents has been investigated for the treatment of allergic and inflammatory conditions, such as asthma and atopic dermatitis, as well as in oncology to reprogram the immunosuppressive tumor microenvironment.
- Other names
- anti-IL-4 antibodyanti-IL4 antibodyanti-IL 4 antibodyanti-IL-4 mAbanti-IL4 mAbanti-IL 4 mAbanti-IL-4 monoclonal antibodyanti-IL4 monoclonal antibodyanti-IL 4 monoclonal antibodyanti-IL-4 neutralizing antibodyanti-IL4 neutralizing antibodyanti-IL 4 neutralizing antibodyanti-IL-4 neutralizing mAbanti-IL4 neutralizing mAbanti-IL 4 neutralizing mAb
02
Targets
IL4R (Interleukin-4 receptor alpha subunit)IL-4 (Interleukin 4)
Beyond the preview
Go deeper on anti-IL-4 neutralizing monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-IL-4 neutralizing monoclonal antibody.